Neoadjuvant Chemotherapy (NACT) in Malignant Peritoneal Mesothelioma (MPeM) treated with Cytoreduction (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC)

MLA

Lynne Chapman, et al. “Neoadjuvant Chemotherapy (NACT) in Malignant Peritoneal Mesothelioma (MPeM) Treated with Cytoreduction (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC).” European Journal of Surgical Oncology, vol. 49, Feb. 2023, p. e60. EBSCOhost, https://doi.org/10.1016/j.ejso.2022.11.201.

APA

Lynne Chapman, Michael G. White, Anneleis Willett, Karen Beaty, Aurelia Matamoros, Melissa Taggart, Wai Chin Foo, Christopher Scally, Paul Mansfield, Anais Malpica, Kanwal Raghav, & Keith F. Fournier. (2023). Neoadjuvant Chemotherapy (NACT) in Malignant Peritoneal Mesothelioma (MPeM) treated with Cytoreduction (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC). European Journal of Surgical Oncology, 49, e60. https://doi.org/10.1016/j.ejso.2022.11.201

Chicago

Lynne Chapman, Michael G. White, Anneleis Willett, Karen Beaty, Aurelia Matamoros, Melissa Taggart, Wai Chin Foo, et al. 2023. “Neoadjuvant Chemotherapy (NACT) in Malignant Peritoneal Mesothelioma (MPeM) Treated with Cytoreduction (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC).” European Journal of Surgical Oncology 49 (February): e60. doi:10.1016/j.ejso.2022.11.201.